---
schema_version: "secwatch.filing_event.v1"
accession: "0001386570-25-000015"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2025-10-06T23:59:59+00:00"
generated_at: "2026-05-17T04:33:34.018119+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Niagen Bioscience raises FY2025 net sales growth guidance to 25%-30% YoY

## Summary
- Full-year 2025 net sales outlook raised to 25%-30% YoY growth from prior 22%-27%.
- CEO cites FDA reversal on DSHEA drug preclusion rule for NMN as potential awareness driver.
- Press release notes every NMN supplement tested infringes on Niagen's patent portfolio.
- Niagen (patented NR) claims superior bioavailability vs. NMN, with three in four NMN products failing label claims.

## SEC filing metadata
- accession: 0001386570-25-000015
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2025-10-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000138657025000015/0001386570-25-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000138657025000015/cdxc-20251006.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001386570-25-000015
- JSON: https://secwatch.observer/filing/0001386570-25-000015.json
- Plain text: https://secwatch.observer/filing/0001386570-25-000015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.